Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 3,458 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $28.33, for a total value of $97,965.14. Following the completion of the sale, the insider owned 310,506 shares in the company, valued at approximately $8,796,634.98. This trade represents a 1.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Soleil Boughton also recently made the following trade(s):
- On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total value of $691,808.05.
Hims & Hers Health Trading Down 0.6%
HIMS stock opened at $27.66 on Friday. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $65.30. The stock has a market cap of $6.45 billion, a price-to-earnings ratio of -43.90 and a beta of 2.42. The company has a fifty day moving average price of $31.67 and a two-hundred day moving average price of $26.75. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on HIMS. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Needham & Company LLC lifted their price target on Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Canaccord Genuity Group upped their price objective on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research report on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $32.50.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System boosted its stake in shares of Hims & Hers Health by 3,404.9% in the second quarter. California State Teachers Retirement System now owns 8,000,068 shares of the company’s stock valued at $277,362,000 after buying an additional 7,771,816 shares during the period. State Street Corp increased its stake in Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after acquiring an additional 132,311 shares during the period. Geode Capital Management LLC increased its stake in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after acquiring an additional 608,950 shares during the period. Bank of America Corp DE raised its holdings in Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after acquiring an additional 2,877,550 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after acquiring an additional 1,600,004 shares in the last quarter. 63.52% of the stock is owned by institutional investors.
Hims & Hers Health News Summary
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: Hims & Hers continues to show strong top-line momentum: second-quarter revenue rose 38.2% year over year to $753.2 million and exceeded analyst expectations. The company also raised its 2026 revenue outlook, supported by weight-loss treatments, international expansion and artificial-intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
- Neutral Sentiment: Analyst sentiment remains cautious. The consensus rating is “Hold,” with analysts recognizing the company’s growth opportunities while citing profitability pressure and uncertainty related to regulatory oversight.
- Negative Sentiment: Several investor-rights firms announced or promoted a securities-fraud class action against Hims & Hers and certain executives. The case covers investors who acquired securities between August 4, 2025, and July 29, 2026; investors must move for lead-plaintiff status by November 2, 2026. The repeated announcements increase concerns about potential legal expenses, penalties, management distraction and reputational damage. Rosen Law Firm HIMS Class Action Announcement
- Negative Sentiment: The litigation is tied to allegations stemming from an FTC complaint, including potentially deceptive privacy and billing practices. Claims that consumer health information may have been shared with advertising platforms and that customers may have been charged soon after submitting prescription-intake forms create risks of enforcement actions and additional compliance costs. These claims remain allegations. Kessler Topaz HIMS Investor Alert
- Negative Sentiment: Insider Soleil Boughton sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s holdings by about 1.1%, making it a relatively small and scheduled sale, but it adds a modest negative signal amid the broader legal uncertainty. Hims & Hers Insider Sale
Hims & Hers Health Company Profile
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
